Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

Pınar Gursoy1 · Ali Murat Tatlı2 · Dilek Erdem3 · Erdem Goker1 · Emir Celik4 · Nebi Serkan Demirci4 · Abdullah Sakin5 · Muhammed Mustafa Atci5 · Ertuğrul Bayram6 · Tuğba Akin Telli7 · Burak Bilgin8 · Ahmet Bilici9 · Muhammed Mustafa Atci5 · Ertuğrul Bayram6 · Tuğba Akin Telli7 · Burak Bilgin8 · Ahmet Bilici9 · Baran Akangunduz10 · Sevinç Ballı11 · Ahmet Demirkazık11 · Fatih Selçukbircik12 · Serkan Menekse13 · Eyyüp Cavdar14 · Akın Ozturk15 · Esma Türkmen Bekmez16 · Serdal Turhal17 · Sadettin Kilickap18 · Hasan Çağrı Yıldırım18 · Başak Oyan19 · Asude Aksoy20 · Fatma Paksoy Turkoz21 · Engin Kut13 · Nuran Katgi22 · Teoman Sakalar23 · Murat Akyol24 · Halil Ibrahim Ellez25 · Atakan Topçu26 · Atike Pınar Erdoğan27 · Kezban Nur Pilanci28 · Engin Hedem29 · Hacı Arak30 · Nadiye Akdeniz31 · Özkan Alan32 · Burcu Yapor33 · Deniz Nart1 · Perran Fulden Yumuk12

Received: 30 November 2021 / Accepted: 11 March 2022 / Published online: 5 April 2022
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

Abstract

Objectives To compare the survival of first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with rare EGFR exon 18 and exon 20 mutation-positive non-small cell lung cancer (NSCLC).

Materials and methods We retrospectively evaluated survival characteristics of 125 patients with EGFR exon 18 and exon 20 mutated NSCLC who received erlotinib or afatinib as first line treatment between 2012 and 2021 from 34 oncology centres. Since exon 20 insertion is associated with TKI resistance, these 18 patients were excluded from the study.

Results EGFR exon 18 mutations were seen in 60%, exon 20 mutations in 16%, and complex mutations in 24% of the patients with NSCLC who were evaluated for the study. There were 75 patients in erlotinib treated arm and 50 patients in afatinib arm. Patients treated with erlotinib had progression-free survival time (PFS) of 8.0 months and PFS was 7.0 months in the afatinib arm (p = 0.869), while overall survival time (OS) was 20.0 vs 24.8 months, respectively (p = 0.190). PFS of exon 18 mutated arm was 7.0 months, exon 20 mutated arm was 4.3 months, and complex mutation positive group was 17.3 months, and this was statistically significant (p = 0.036). The longest OS was 32.5 months, seen in the complex mutations group, which was not statistically different than exon 18 and in exon 20 mutated groups (21.0 and 21.2 months, respectively) (p = 0.323).

Conclusion In this patient group, especially patients with complex mutations are as sensitive to EGFR TKI treatment similar to classical mutations, and in patients with rare exon 18 and exon 20 EGFR mutation both first- and second-generation EGFR-TKIs should be considered, especially as first- and second-line options.

Keywords Exon 18 · Exon 20 · Erlotinib · Afatinib · NSCLC

Introduction

Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related deaths worldwide (Herbst et al. 2008). Frequency of epidermal growth factor receptor (EGFR) mutation in patients with NSCLC has been found to be approximately 10–20% in European populations and 50% in Asian populations (Yuankai et al. 2014). Exon 19 and exon 21 L858R are called “classical EGFR mutations” and account for 90% of EGFR mutations in all NSCLC (Rafael et al. 2009). These classical EGFR mutations show high sensitivity to tyrosine kinase inhibitors (TKIs). In studies comparing TKIs with chemotherapy, it has been shown that patients treated with TKIs have longer progression-free survival (PFS) (Rafael et al. 2012).

Other EGFR mutations are called uncommon EGFR mutations (u-EGFRm), and these account for
approximately 10–20% of all EGFR mutations. Among the u-EGFR mutations, exon 18 and exon 20 mutations were found to be 2–4% and 4–5%, respectively (Rafael et al. 2010; Kobayashi et al. 2013). Clinical characteristics, their response to TKIs and prognosis of u-EGFRm positive patients are not completely clear (Pao et al. 2010; Mitsudomi et al. 2006).

Among the TKIs, erlotinib is a first-generation reversible TKI, while afatinib is a second-generation irreversible TKI. Erlotinib in the OPTIMAL study and afatinib in the LUX-LUNG-3 study showed PFS advantage over standard chemotherapy (Zhou et al. 2011; Sequist 2012). There are no clinical study comparing the efficacy of erlotinib and afatinib in patients with both “classical EGFR mutations” and “uncommon mutations” in the literature.

The aim of this study is to determine the characteristics of advanced stage NSCLC patients with EGFR exon 18 and 20 mutations, and to reveal the survival outcomes of patients treated with first- and second-generation TKI in NSCLC harbouring these rare mutations.

### Materials and methods

#### Study design

In our study, the data of 143 patients with NSCLC who were positive for EGFR exon 18 and exon 20 mutations treated with erlotinib or afatinib in 34 centers from Turkey between 2012 and 2021 were evaluated retrospectively. EGFR mutation positivity in patients with NSCLC was determined by pyrosequencing method or real time PCR. Since exon 20 insertion is associated with TKI resistance, these 18 patients were excluded from the study. However, we wanted to specify the data of 18 patients separately. Remaining 125 patients included in the study were divided into 3 groups. The first group consisted of patients with only exon 18 mutations, the second group with only exon 20 mutations, and the third group with complex mutations. Complex mutation was defined as more than one mutation positivity on the condition with one of the mutations was seen on exon 18 or exon 20. Flow chart of the study is presented in Fig. 1. Sex, age, smoking status, ECOG performance score (PS), stages, metastasis sites, treatments received before and after, side effects, date of progressive disease and death of the patients

![Flowchart of the study](image-url)
were recorded. Progression-free survival (PFS) was defined as the time between the onset of TKI and the date of progression, or death, and overall survival (OS) was defined as the time between the date of diagnosis and the date of death or the last contact date. Among these three groups, general characteristics of the patients, survival outcomes, and relationship between the survival time and the type of TKI treatment were evaluated retrospectively.

Statistical analysis

IBM SPSS Statistics Version 22 package program was used for statistical analysis. Whether the data were normally distributed was determined by Kolmogorov–Smirnov and Shapiro–Wilk tests. Mann–Whitney U test was used to compare continuous variables between groups, Chi-square test and Fisher’s exact test were used to compare categorical variables. Kaplan–Meier test was used for survival analysis. Results are presented as, median (min–max) and number (percentage). A p value of <0.05 was considered statistically significant in all statistical analyses.

Results

Patients

Median age of 125 patients was 63.1 (37.0–86.0). Exon 18, exon 20 and complex mutations rates were 60% (75 patients), 16% (20 patients) and 24% (30 patients), respectively. Exon 18 and complex mutations were observed more in males, and the frequency of exon 20 mutations was equal in both genders (p=0.196). There were 75 patients (60%) treated with erlotinib and 50 patients (40%) with afatinib. EGFR-TKI was the first line treatment in 53.6% of the patients, second line in 39.2%, third line in 6.4% and fourth line in 0.8%. General characteristics of the patients are presented in Table 1.

Survival outcomes

The median follow-up time of all patients was 16.7 months (1.3–112.7). Follow-up period was 16.5 months in the erlotinib arm and 17.4 months in the afatinib arm.

OS of all patients was 21.4 months (95% CI 16.1–26.6), while PFS was 7.2 months (95% CI 5.1–9.3). When PFS and OS were compared according to the type of TKI used, PFS was 8.0 months (95% CI 4.7–11.3) in the erlotinib arm and 7.0 months (95% CI: 4.4–9.6) in the afatinib arm. OS seemed longer in the afatinib arm than in the erlotinib arm (24.8 months vs. 20.0 months, respectively). However, no statistically significant difference was found between the two groups in both PFS and OS comparisons (Fig. 2A, B).

PFS in the Exon 18, Exon 20 and complex mutation groups were 7.0 months (95% CI 5.9–8.1), 4.3 months (95% CI 2.1–6.5) and 17.3 months (95% CI 8.5–26.1), respectively, and there was a statistically significant difference between these 3 groups (p=0.036) (Fig. 3).

The distribution of rare mutations is presented in Fig. 4. Exon 18 G719X point mutation was the most mutation. This mutation was found alone in 85%, and it was also found together with exon 19 deletion in 3% and with exon 21 mutation in 12% of patients. Thirty-six exon 18 G719X positive patients received erlotinib and 24 patients received afatinib. The survival rates are shown in Table 2.

When insertions of exon 20 was excluded, the second most common mutation was S768I, which was usually positive alone. Nine patients with this mutation received erlotinib and six received afatinib (Table 2).

When the PFSs were evaluated according to the TKI types of the patients in the exon groups, statistical significance was not found in all groups, although the PFS was longer in those who received afatinib than those who received erlotinib. Similar results were also observed in OS. The results are presented in Table 2.

When OSs were compared according to exon subgroups, the longest OS was found to be 32.5 months in complex mutations, while it was 21.0 and 21.2 months seen in Exon 18 and exon 20 mutations, respectively (p=0.323).

Exon 19 or exon 21 mutations were present in 22 patients in the complex mutation group, and PFS time of these patients was 17.4 months (95% CI 6.6–28.2) and OS was 24.3 months (95% CI 0.0–89.4). In patients without exon 19 and/or exon 21 alterations, PFS was 8.3 months (95% CI 0.0–21.4) and OS was 11.5 months (95% CI 0.0–42.5). In the complex mutation group, there was no difference in terms of PFS and OS between erlotinib or afatinib treatments, regardless of exon 19 or exon 21 status.

Overall response rate of the patients was similar in the erlotinib and afatinib arms (53.3 vs 52%, p = 0.218) (Table 3).

There was no difference between the TKI treatment groups in terms of gender and metastatic status. In the erlotinib arm, PFS of the patients who had never smoked was statistically longer than those who were ex-smokers and current smokers (12.0 vs 8.0 vs 3.5 months, p=0.008), while no statistical difference was found in the afatinib arm (9.6 vs 6.0 vs 8.5 months, p=0.087).

There was no difference between the exon groups, when sex and metastasis status were compared. However, in exon 18 mutation-positive patients, the PFS was longest in the never-smoker group, and a statistical difference was found compared to the patients who quit smoking and are still smoking (9.6 vs 6.6 vs 3.7 months, p=0.013). There were no PFS difference between smoking status in exon 20 and complex mutations (p=0.118 vs p=0.331).
Patients received TKIs mostly as first-line treatment, and the PFS in the first line was 8.9 months, 7.1 months in the second line, 3.4 months in the third line, and 3.5 months in the fourth line \((p=0.009)\). There were no OS difference between the line of treatment \((p=0.233)\).

### Results of patients with exon 20 insertion

Since exon 20 insertion is associated with TKI resistance, this mutation was analysed in itself. Of those 18 patients with exon 20 insertion, 10 patients were male, and 50% were non-smokers. In this group, 7 patients (38.3\%) received erlotinib, 6 patients (33.3\%) afatinib, and 5 patients (27.7\%) gefitinib. Median PFS of the whole group was 8.7 months \((95\% \text{ CI } 3.1–14.3)\). In those who received erlotinib PFS was 7.0 months \((95\% \text{ CI } 1.0–14.2)\), in afatinib treated patients PFS was 8.7 months \((95\% \text{ CI } 1.0–20.5)\), and in gefitinib 15.0 months \((95\% \text{ CI } 1.0–24.1)\) \((p=0.479)\). Median OS was 26.4 months \((95\% \text{ CI } 20.0–32.8)\) for the entire group. It was 24.0 months \((95\% \text{ CI } 20.7–27.3)\) with erlotinib, 31.4 months \((95\% \text{ CI } 22.7–40.1)\) with afatinib, and 28.5 months \((95\% \text{ CI } 11.1–46.0)\) with gefitinib. There was no statistically significant difference between the TKIs. In this patient group, only the PFS values of male patients were found to be significantly longer than female patients \((12.0 \text{ months vs. } 3.2 \text{ months}, p=0.003)\).

### Table 1 Baseline clinical and demographic characteristics of patients

|                | Patients, \(n\) (%) | Patients with EGFR exon 18 mutations, \(n\) (%) | Patients with EGFR exon 20 mutations, \(n\) (%) | Patients with complex EGFR mutations, \(n\) (%) |
|----------------|---------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Age (years) mean (min–max) | 125 (63.1 ± 10.6) | 75 (60) (62.7 ± 10.6) | 20 (16) (61.0 ± 11.41) | 30 (24) (65.4 ± 10.0) |
| Sex, \(n\) (%) |                     |                                               |                                               |                                               |
| Female     | 46 (36.8)           | 23 (30.6)                                     | 10 (50.0)                                     | 13 (43.3)                                     |
| Male       | 79 (63.2)           | 52 (69.3)                                     | 10 (50.0)                                     | 17 (56.6)                                     |
| Smoking, \(n\) (%) |                   |                                               |                                               |                                               |
| Never smoker | 51 (40.8)         | 28 (37.3)                                     | 8 (40.0)                                      | 15 (50)                                       |
| Former smoker | 59 (47.2)         | 37 (49.3)                                     | 8 (40.0)                                      | 14 (46.6)                                     |
| Current smoker | 15 (12.0)        | 10 (13.3)                                     | 4 (20.0)                                      | 1 (3.3)                                       |
| Histology, \(n\) (%) |                 |                                               |                                               |                                               |
| Adenocarcinoma | 116 (92.8)       | 69 (92.0)                                     | 19 (95.0)                                     | 28 (93.3)                                     |
| Squamous cell | 5 (4.0)           | 4 (5.3)                                       | 0                                             | 1 (3.3)                                       |
| Large cell  | 1 (0.8)            | 0                                             | 1 (5.0)                                       | 0                                             |
| Mixt        | 3 (2.4)            | 2 (2.6)                                       | 0                                             | 1 (3.3)                                       |
| ECOG, \(n\) (%) |                |                                               |                                               |                                               |
| 0           | 22 (17.6)          | 17 (22.6)                                     | 3 (15.0)                                      | 2 (6.6)                                       |
| 1           | 82 (65.6)          | 46 (61.3)                                     | 13 (65.0)                                     | 23 (76.6)                                     |
| 2           | 17 (13.6)          | 11 (14.6)                                     | 1 (5.0)                                       | 5 (16.6)                                      |
| 3           | 4 (3.2)            | 1 (1.3)                                       | 3 (15.0)                                      | 0                                             |
| Stage at presentation, \(n\) (%) |           |                                               |                                               |                                               |
| I           | 6 (4.8)            | 5 (6.6)                                       | 1 (5)                                         | 0                                             |
| II          | 6 (4.8)            | 4 (5.3)                                       | 0                                             | 2 (6.6)                                       |
| III         | 12 (9.6)           | 8 (10.6)                                      | 3 (15)                                        | 1 (3.3)                                       |
| IV          | 101 (80.8)         | 58 (77.3)                                     | 16 (80)                                       | 27 (90)                                       |
| Metastasis, \(n\) (%) |             |                                               |                                               |                                               |
| Solitary    | 48 (38.4)          | 33 (44)                                       | 5 (25)                                        | 10 (33.3)                                     |
| Multiple    | 77 (61.6)          | 42 (56)                                       | 15 (75)                                       | 20 (66.6)                                     |
| De-novo disease, \(n\) (%) |              |                                               |                                               |                                               |
| Yes         | 101 (80.0)         | 58 (77.3)                                     | 16 (80.0)                                     | 27 (90.0)                                     |
| No          | 24 (20.0)          | 17 (22.6)                                     | 4 (20.0)                                      | 3 (10.0)                                      |
| Brain metastasis, \(n\) (%) |           |                                               |                                               |                                               |
| Yes         | 30 (24.0)          | 18 (24.0)                                     | 6 (30.0)                                      | 6 (20.0)                                      |
| No          | 95 (76.0)          | 57 (76.0)                                     | 14 (70.0)                                     | 24 (80.0)                                     |
Most common adverse event in the erlotinib arm was rash (54.6%), followed by mucositis (41.3%), anemia (32.0%), diarrhea (28.0%), and elevated transaminase (20%). Rash (66%), diarrhea (58%), anemia (36%), mucositis (28%), and elevated transaminases (24%) were observed frequently with afatinib.

The incidence of grade 3–4 adverse events was 13.3% in the erlotinib arm, and 20% in the afatinib arm. Due to side effects, treatment was interrupted in 20 (16.0%) patients and dose reduction was made in 17 (13.6%) patients. In 7 patients (5.6%), the treatment was permanently discontinued. Side effects that led to treatment discontinuation were rash, elevated transaminases, and interstitial lung disease. Interstitial lung disease was observed only in 1 patient (2%) with afatinib, and treatment was permanent discontinued.

When the relationship between side effects and survival was evaluated, PFS was longer in patients with mucositis (14.2 months vs. 6.0 months, \( p = 0.004 \)), and OS was longer in patients with rash (24.7 months vs 17.8 months, \( p = 0.080 \)).
In our study, no difference was found in terms of survival when first- and second-generation EGFR-TKIs were compared in NSCLC patients with rare mutations in exon 18 and exon 20. In addition, the complex EGFR mutations which were almost one fourth of our study group showed the highest sensitivity to the TKIs treatment.

In the literature, there is only one study in which 18 patients were retrospectively compared first- and second-generation TKI treatments in patients with NSCLC carrying uncommon EGFR mutations (Tanaka et al. 2019). In this study, there was a significant PFS difference in favour of afatinib compared to erlotinib (17.1 and 5.5 months).

**Table 2** Comparison of survival times according to TKI type in exon groups

| Exon   | TKI   | n   | PFS (months) (median) | P value | OS (months) (median) | P value |
|--------|-------|-----|-----------------------|---------|----------------------|---------|
| Exon 18| Erlotinib | 45  | 5.6 (2.9–8.3)         | 0.206   | 23.9 (11.2–36.7)     | 0.691   |
|        | Afatinib | 30  | 7.0 (4.3–9.7)         |         | 19.0 (14.9–23.1)     |         |
| Exon 20| Erlotinib | 13  | 4.0 (0.4–7.6)         | 0.966   | 16.7 (10.4–23.0)     | 0.417   |
|        | Afatinib | 7   | 4.3 (1.8–6.8)         |         | 34.7 (17.1–52.3)     |         |
| Complex| Erlotinib | 17  | 11.7 (7.2–16.2)       | 0.674   | 20.0 (6.6–33.4)      | 0.133   |
|        | Afatinib | 13  | 18.7 (6–31.4)         |         | 33.9 (25.8–42.0)     |         |
| G719X  | Erlotinib | 36  | 4.9 (1.0–8.7)         | 0.328   | 17.3 (12.5–22.0)     | 0.489   |
|        | Afatinib | 24  | 8.8 (6.7–10.8)        |         | 21.0 (16.2–25.7)     |         |
| S768I  | Erlotinib | 10  | 9.7 (0.0–23.6)        | 0.111   | 16.7 (11.8–21.4)     | 0.566   |
|        | Afatinib | 5   | 3.1 (1.1–5.02)        |         | 34.7 (0–77.4)        |         |
| Exon 20| Erlotinib | 7   | 7.0 (1.0–14.2)        | 0.479   | 24.0 (20.7–27.3)     | 0.396   |
| Insertion| Afatinib | 6   | 8.7 (1.0–20.5)        |         | 31.4 (22.7–40.1)     |         |
| Gefitinib |        | 5   | 15.0 (1.0–24.1)       |         | 28.5 (11.1–46.0)     |         |

**Table 3** Best response rates of afatinib and erlotinib

| Type of response (%) | Erlotinib (n:75) | Afatinib (n:50) |
|----------------------|------------------|-----------------|
| Complete response    | 5.3              | 6.0             |
| Partial response     | 48.0             | 46.0            |
| Stable disease       | 5.3              | 18.0            |
| Progression          | 41.3             | 30.0            |
| Overall response rate (ORR) | 53.3       | 52.0            |
| Disease control rate (DCR) | 58.6          | 70.0            |

**Discussion**

In our study, no difference was found in terms of survival when first- and second-generation EGFR-TKIs were compared in NSCLC patients with rare mutations in exon 18 and exon 20. In addition, the complex EGFR mutations which were almost one fourth of our study group showed the highest sensitivity to the TKIs treatment.

In the literature, there is only one study in which 18 patients were retrospectively compared first- and second-generation TKI treatments in patients with NSCLC carrying uncommon EGFR mutations (Tanaka et al. 2019). In this study, there was a significant PFS difference in favour of afatinib compared to erlotinib (17.1 and 5.5 months).
respectively, \( p = 0.048 \). However, in this small study differences between mutation subtypes were not specified.

Most common rare mutation in our patient group was exon 18 mutations. Although PFS was longer in patients treated with afatinib, no statistically significant difference was found when compared with erlotinib. G719X point mutation on exon 18 was detected in 56% of the whole group. It was seen alone in 85%, and was together with exon 19 deletions in 3% and exon 21 mutations in 12% of patients. Although G719X is the most common point mutation in the literature, it has been reported that it is associated with complex mutations at a rate of 90% (Passaro et al. 2020). In the post-hoc analysis of LUX-lung 2, LUX-lung 3 and LUX-lung 6 studies, PFS was 13.8 months, OS 26.9 months, and Objective Response Rate (ORR) was 78% in patients receiving afatinib with G719X mutation (Sequist et al. 2012). In a retrospective study by Chiu, PFS was 6.5 months and ORR 50% with erlotinib/gefitinib treatment in this patient group (Chiu et al. 2015). In our study, it was observed that G719X positive patients had a shorter PFS and a lower ORR compared to the literature. We think that this may be due to the low number of patients with other mutations accompanying the G719X mutation in our study.

S768I mutation in exon 20 is the second most common mutation, when exon 20 insertion is excluded (Sun et al. 2009). In accordance with the literature, this mutation was usually found alone in our study. In Zhang’s retrospective study, although the ORR was 27.3% in patients receiving erlotinib, PFS was found to be 8.0 months (range 4.3–11.8 months). According to the post-hoc analysis results of the LUX-lung 2–3–6 studies, the S768I mutation had the longest PFS duration (14.7 months). In our study, although PFS and ORR of those who received erlotinib were similar to the literature, very short PFS values were seen with afatinib. Having said that, 34.7 months of OS was seen with afatinib in this subgroup.

The frequency of complex mutations is approximately 25% according to the latest data, and it was also seen in our study as 24% (Kim et al. 2016). Complex mutations have been shown to respond better to EGFR-TKIs compared to single rare mutations. Especially its co-occurrence with exon 19 del or L858R mutations might be a strong indicator of its sensitivity to EGFR-TKIs. In our study, the PFS and OS values of patients having complex mutations with exon 19 deletions or exon 21 mutations were also longer than those without. In a retrospective study by Keam et al. complex and classical mutations showed the same treatment efficacy to EGFR-TKI (Keam et al. 2014). In the multicenter study of Passaro et al. TKI response of patients with complex mutations was superior in terms of both PFS and OS compared to patients with exon 18 mutations (Passaro et al. 2019). In our study, a statistically significant PFS advantage was observed in patients with complex mutations compared to only exon 18 or exon 20 mutated patients.

Some of the preclinical studies have shown that second generation TKIs are more effective in rare mutations than first- and third- generation TKIs (Gristina et al. 2020). Tanaka et al. compared afatinib with first generation TKIs in patients with complex mutations. The authors reported a statistically longer PFS and a better ORR in favor of afatinib (Tanaka et al. 2019). Similar to the literature, we also found a non-significant longer PFS with afatinib than erlotinib. This might be secondary to low number of patients in both treatment groups.

Recent studies on rare mutations are summarized in Table 4.

Exon 20 insertion in the tyrosine kinase domain is located after the C-helix, it is assumed to be resistant to EGFR-TKIs. In this subtype, the contribution of chemotherapy to PFS is 5 months, while the contribution of TKI to PFS is around 2.5 months. It has been suggested that exon 20 insertion excludes another EGFR mutation (Wu et al. 2008). However, there are cases of exon 20 insertion seen with exon 19 deletion and L858R mutation in the literature. In that case, survival times were observed to be longer with TKI treatment. In a retrospective study evaluating 77 patients, ORR was 24.3%, and PFS was 11.9 months with afatinib (Yang et al. 2019). These data suggest that some exon 20 insertions seen as a part of complex mutations are clinically sensitive to afatinib. Nevertheless, PFS was found to be 2.7 months in the LUX-lung studies, and variants sensitive to TKIs may not have been represented at a high rate due to the high heterogeneity of exon 20 insertion in these studies. In a study from Korea, PFS was found to be 11.4 months in a patient with only exon 20 insertion. The reason for this was stated that different variants in the amino acid sequence might affect the response to treatment (Byeon et al. 2019). Kosaka et al. showed that replacing Asp770 with Gly770 restored susceptibility to EGFR TKIs by allowing access to Arg776 (Kosaka et al. 2017). Similar to the literature, we also found that PFS value of this group was found to be longer than the literature. In particular, PFS values of 5 patients who received gefitinib were reported as the longest TKI responses in the literature, and exon 19 deletion or exon 21 mutation were also detected in only these 5 patients in the whole group. Exon 20 insertion combined with these mutations has a median PFS of 11.3 months. The reason for the long PFS in the literature might be the presence of these complex mutations or different variants which are very sensitive to TKIs. However, studies with a larger number of patients are needed to reveal these results clearly.

In our study, PFS of patients who received first- and second-line EGFR-TKIs was found to be statistically longer than those who received third-line and later. In the literature, PFS values are very short after the third line (Chiu 2015). Therefore, treatment of NSCLC with EGFR-TKI as first-line
or second-line therapy is considered a reasonable option for patients with rare mutations.

Limitations of this study were that it was designed retrospectively, and the selected agents were the physician’s preference and could affect the results. In addition, methods used in each center to detect the EGFR mutations might have affected the mutation frequency and positivity rate. Despite these limitations, our study has the largest number of patients in the literature comparing afatinib and erlotinib treatment in patients with rare exon 18 and exon 20 mutations. Although afatinib provided longer survivals in terms of treatment efficacy, no statistically significant difference was found. In this patient group, especially patients with complex mutations are as sensitive to EGFR TKI treatment as classical mutations, and in patients with rare exon 18 and exon 20 mutations, both first- and second-generation TKIs

Table 4  Clinical outcomes. G719X mutation–S768I mutation–complex mutation treated with TKI

| Mutation     | Study (Reference) | EGFR Mutation(S), N treated with EGFR I | EGFR I used                  | ORR (%) | DCR (%) | Median PFS, months (95% CI) | Median OS, months (95% CI) |
|--------------|-------------------|----------------------------------------|-------------------------------|---------|---------|----------------------------|----------------------------|
| G719X        | Chiu et al. (2015) | G719X, n = 78                          | Erlotinib/Gefitinib           | 36.8    | 72.4    | 6.30                       | NR                         |
|             | Kobayashi and Mitsu-domi (2016) | G719X, n = 148 | Erlotinib/Gefitinib         | 65.5    | 32.0    | NR                         | NR                         |
| Kate et al. (2019) | G719X n = 5 | Erlotinib/Gefitinib | 50.0 | NR | 9 | NR |
| Yang et al. (2015) | G719X single n = 8, complex n = 6 | Afatinib | 77.8 | NR | 13.8 | 26.9 |
| Gursoy et al. | G719X n = 36 | Erlotinib | 47.2 | 55.5 | 4.9 | 17.3 |
| Gursoy et al. | G719X n = 24 | Erlotinib | 58.2 | 79.0 | 8.8 | 21.0 |
| S768I        | Kobayashi and Mitsu-domi (2016) | S768I, n = 12 | Erlotinib/Gefitinib | 42.0    | 58.0    | NR                         | NR                         |
| Chiu et al. (2015) | S768I, n = 6 | Erlotinib/Gefitinib | 33.3 | 66.7 | NR | NR |
| Kate et al. (2019) | S768I, n = 2 | Erlotinib/Gefitinib | 0.0 | 0.0 | 1 | NR |
| Yang et al. (2015) | S768I single n = 1, complex n = 7 | Afatinib | 100 | 100 | 14.7 | NR |
| Gursoy et al. | S768I n = 9 | Erlotinib | 44.4 | 55.5 | 9.7 | 16.7 |
| Gursoy et al. | S768I n = 6 | Afatinib | 16.6 | 33.2 | 3.1 | 34.7 |
| Compound     | Wu and shih (2016) | E709 compound mutations, n = 13 | Erlotinib/Gefitinib | 50.0    | 72.2    | 6.2 | 29.3 |
| Kobayashi and Mitsu-domi (2016) | E709 Compound mutations, n = 15 | Erlotinib/Gefitinib | 53.0    | 86.7    | NR | NR |
| Chen et al. (2016) | S768I + L858R, n = 4 | Erlotinib/Gefitinib | 20.0 | 70.0 | 2.7 | 14.5 |
| Chiu et al. (2015) | S768I + G719X n = 10 | Erlotinib/Gefitinib | 50.0 | 100 | NR | NR |
| Gursoy et al | Compound mutations n = 17 | Erlotinib | 70.5 | 82.2 | 11.7 | 20.0 |
| Gursoy et al | Compound mutations n = 13 | Afatinib | 61.4 | 69.0 | 18.7 | 33.9 |
| EX 20 Insertion | Xu et al. (2016) | Multiple ex20 insertion, n = 12 | Erlotinib/Gefitinib | 8.3     | 58.3    | 2.0 | 16.96 |
| Beau-Faller et al. (2014) | Multiple ex20 insertion, n = 19 | Erlotinib/Gefitinib | 5.0 | 36.0 | 2 | 9.5 |
| Kate et al. (2019) | Multiple ex20 insertion, n = 7 | Erlotinib/Gefitinib/Afatinib | 0.0 | 0.0 | 1.9 | NR |
| Yang et al. (2015) | Multiple ex20 insertion, n = 23 | Afatinib | 8.7 | 65.0 | 2.7 | 9.2 |
| Gursoy et al | Multiple ex20 insertion, n = 7 | Erlotinib | 28.5 | 42.7 | 7.0 | 24.0 |
| Gursoy et al | Multiple ex20 insertion, n = 5 | Gefitinib | 60 | 62.2 | 15.0 | 28.5 |
| Gursoy et al | Multiple ex20 insertion, n = 6 | Afatinib | 50 | 50 | 8.7 | 31.4 |

**ORR** objective response rate, **DCR** disease control rate, **PFS** progression-free survival, **OS** overall survival, **NR** not reported
should be considered, especially as first- and second-line options.

Acknowledgements None.

Funding No role for any funding source.

Declarations

Conflict of interest The authors declare no conflicts of interest.

Ethical approval This study was approved by Ethical Committee (21-4.1T_10_0). All patients gave written informed consent.

References

Beau-Faller M, Prim N, Ruppert A-M, Nanni-Metéllus I, Lacave R, Lacroix L et al (2014) Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol 25:126–131

Byeon S, Kim Y, Won Lim S, Cho J-H, Park S, Lee J et al (2019) Clinical outcomes of EGFR exon 20 insertion mutations in advanced non-small cell lung cancer in Korea. Cancer Res Treat 51(2):623–631

Chen D, Song Z, Cheng G (2016) Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations. Onco Targets Ther 2016(9):4181–4186

Chiu C-H, Yang C-T, Huang M-S, Su W-C, Lai R-S et al (2015) Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/ S768I mutations. J Thorac Oncol 10:793–9

Grigors T, Malapelle U, Galvano A, Pisapia P, Pepe F, Rolfo C et al (2020) The significance of epidermal growth factor receptor uncommon advanced mutations in non-small cell lung cancer: a systematic review and critical appraisal. Cancer Treat Rev 85:101994

Herbst RS, Heymach JV, Lippman SM (2008) Lung Cance. N E J M 2008(359):1367–1380

Kate S, Chougule A, Josh A, Noronha V, Patil V, Dusane R et al (2019) Outcome of uncommon EGFR mutation positive non-small-cell lung cancer patients: a single center retrospective analysis. Lung Cancer (aucll) 2019(10):1–10

Keam B, Kim DW, Park JH, Lee J-O, Kim T-M, Lee S-H et al (2014) Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. Int J Clin Oncol 19:594–600

Kim EY, Cho EN, Park HS, Hong J-Y, Lim S, Youn J-P et al (2016) Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Ther 2016(17):237–245

Kobayashi S, Canepa HM, Bailey AS et al (2013) Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013(8):45–51

Kobayashi Y, Mitsudomi T (2016) Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci 107:1179–1186

Kosaka T, Tanizaki J, Paranal RM, Endoh H, Lydon C, Capelletti M et al (2017) Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors. Cancer Res 2017(77):2712–2722

Mitsudomi T, Kosaka T, Yatabe Y (2006) Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 11(3):190–8

Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760–774

Passaro A, Prelaj A, Bonanno L, Tiseo M, Tuzi A, Proto C et al (2019) Activity of EGFR TKIs in caucasian patients with NSCLC harboring potentially sensitive uncommon EGFR mutations. Clin Lung Cancer 2019(20):e186–e194

Passaro A, Mok T, Peters S, Popat S, Ahn M-J, Marinis F (2020) Recent advances on the role of EGFR TyrosineKinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations. J Thorac Oncol 16(5):764–773

Rafael R, Teresa M, Cristina Q, Rut P, Felipe C, Carlos C et al (2009) Spanish lung cancer group. screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958–67

Rafael R, Santiago V, Benlloch Susana, Taron Miquel (2010) Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer. Curr Opin Oncol 22(2):112–20

Rafael R, Enric C, Radj G, Alain V, Bartomeu M, Enrique F et al (2012) Spanish lung cancer group in collaboration with groupe Français de Pneumo-Cancérologie and associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–46

Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T et al (2012) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27):3327–34

Sun JM, Lee KW, Kim JH, Kim YJ, Yoon HI, Lee JH et al (2009) Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. Jpn J Clin Oncol 39(1):27–32

Tanaka I, Morise M, Kodama Y, Matsui A, Ozawa N, Ozone S et al (2019) Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations. Lung Cancer 127:169–171

Wu JY, Wu SG, Yang CH, Gow CH, Chang YL, Yu CJ et al (2008) Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008(14):4877–4882

Wu J-Y, Shih J-Y (2016) Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer. Onco Targets Ther 9:6137–6145 (Published online 2016 Oct 11)

Xu J, Jin B, Chu T, Dong X, Yang H, Zhang Y et al (2016) EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: a real-world study in China. Lung Cancer 96:87–92

Yang JCH, Sequist L-V, Geater S-L, Tsai C-M, Mok T-S-K, Schuler M et al (2015) Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 16(7):830–838

Yang J-C-H, Schuler M, Popat S, Miura S, Heeke S, Park K et al (2019) Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases. J Thorac Oncol 15(5):803–815

Yuankai S, Joseph S-K-A, Sumitra T, Sankar S, Chun-Ming T, Mai T-K et al (2014) A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014(9):154–162

Published online 2016 Oct 11
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735–742

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Pınar Gursoy1 · Ali Murat Tatlı2 · Dilek Erdem3 · Erdem Goker1 · Emir Celik4 · Nebi Serkan Demirci4 · Abdullah Sakin5 · Muhammed Mustafa Atci6 · Ertuğrul Bayram7 · Tuğba Akın Telli2 · Burak Bilgin8 · Ahmet Biliç9 · Baran Akangunduz8 · Sevinç Balli1 · Ahmet Demirkazik11 · Fatih Selçukbiricik12 · Serkan Menekse13 · Eyyüp Cavidar14 · Akin Ozturk15 · Esma Türkmen Bekmez16 · Serdal Turhal17 · Sadettin Kılıçkap18 · Hasan Çağrı Yıldırım18 · Başak Oyan19 · Asude Aksoy20 · Fatma Paksoy Turkoz21 · Engin Kut13 · Nuran Katgi22 · Teoman Sakalar23 · Murat Akyol24 · Halil İbrahim Ellez25 · Atakan Topçu26 · Atike Pınar Erdoğan27 · Kezban Nur Pilancı28 · Engin Hedem29 · Hacı Arak30 · Nadiye Akdeniz31 · Özkan Alan32 · Burcu Yapor33 · Deniz Nart1 · Perran Fulden Yumuk12

Ali Murat Tatlı
alimurattat@hotmail.com

Dilek Erdem
dilekgurgenyatagi@yahoo.com

Erdem Goker
derdemgoker@gmail.com

Emir Celik
emircelikk@gmail.com

Nebi Serkan Demirci
drserkannebi@yahoo.com

Abdullah Sakin
drsakin@hotmail.com

Muhammed Mustafa Atci
dr_mmatci@hotmail.com

Ertuğrul Bayram
ertugrulbayram84@gmail.com

Tuğba Akın Telli
tugbaakintelli@gmail.com

Burak Bilgin
drbilgin@hotmail.com

Ahmet Biliç
ahmetknover@yahoo.com

Baran Akangunduz
drbaran04@hotmail.com

Sevinç Balli
svncbl@gmail.com

Ahmet Demirkazik
ademirka@gmail.com

Fatih Selçukbiricik
fselcukbiricik@kuh.ku.edu.tr

Serkan Menekse
drsermen@hotmail.com

Eyyüp Cavidar
eyyupcavidar@hotmail.com

Akin Ozturk
onkoakin@gmail.com

Esma Türkmen Bekmez
esma_a143@hotmail.com

Serdal Turhal
turhal@superonline.com

Sadettin Kılıçkap
skilickap@yahoo.com

Hasan Çağrı Yıldırım
hasan-cagri@windowslive.com

Başak Oyan
basakou@yahoo.com

Asude Aksoy
asudeaksoy@hotmail.com

Fatma Paksoy Turkoz
ftm.pksy@gmail.com

Engin Kut
drenginkut@gmail.com

Nuran Katgi
nkatgi@hotmail.com

Teoman Sakalar
dreomansakalar@gmail.com

Murat Akyol
dr-muratakyol@hotmail.com

Halil İbrahim Ellez
h.ibrahimellez@gmail.com

Atakan Topçu
atakantopcu@hotmail.com

Atike Pınar Erdoğan
dr_pinarcan@yahoo.com

Kezban Nur Pilanci
kezbannurgunes@gmail.com

Engin Hedem
enginhenden1@gmail.com

Hacı Arak
harak63@hotmail.com

Nadiye Akdeniz
nadiyeakdeniz21@gmail.com

© Springer
Özkan Alan
ozkan.alan@hotmail.com
Burcu Yapar
dburcuyapar@gmail.com
Deniz Nart
deniznart@yahoo.com
Perran Fulden Yumuk
fuldenyumuk@yahoo.com

1 Ege University School of Medicine, Tulay Aktas Oncology Hospital, 35100 Izmir, Bornova, Turkey
2 Akdeniz University School of Medicine, Antalya, Turkey
3 Samsun Medical Park, Samsun, Turkey
4 Department of Medical Oncology, Cerrahpasa School of Medicine, Istanbul, Turkey
5 Department of Medical Oncology, Professor Doctor Cemil, Taşçıoğlu City Hospital, İstanbul, Turkey
6 Department of Medical Oncology, Cukurova University, Adana, Turkey
7 Marmara University School of Medicine, Marmara University Pendik Education and Research Hospital, Istanbul, Turkey
8 Department of Medical Oncology, Atatürk Chest Disease and Chest Surgery Research and Training Hospital, Ankara, Turkey
9 Medical Oncology, Medipol University, Istanbul, Turkey
10 Department of Medical Oncology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan, Turkey
11 Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey
12 Department of Medical Oncology, Koc University School of Medicine, Istanbul, Turkey
13 Department of Medical Oncology, Manisa City Hospital, Manisa, Turkey
14 Department of Medical Oncology, Namık Kemal University, Tekirdağ, Turkey
15 Clinic of Medical Oncology, University of Health Sciences Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Turkey
16 Health Sciences University Derince Education Research Hospital, Kocaeli, Turkey
17 Department of Medical Oncology, Anadolu Health Center, İstanbul, Turkey
18 Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
19 Department of Medical Oncology, Acıbadem Altunizade Hospital, İstanbul, Turkey
20 Department of Medical Oncology, Firat University, Elazığ, Turkey
21 İstinye University, Medical Park Goztepe Hospital, Istanbul, Turkey
22 Department of Pulmonology, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Izmir, Turkey
23 Department of Medical Oncology, Necip Fazıl City Hospital, Kahramanmaraş, Turkey
24 Bakırçay University Cigli Education and Research Hospital, İzmir, Turkey
25 Department of Medical Oncology, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
26 Department of Medical Oncology, Bezmialem Vakıf University, İstanbul, Turkey
27 Medical Oncology Department, Celal Bayar University, Manisa, Turkey
28 Memorial Bahcelievler Hospital, İstanbul, Turkey
29 Necmettin Erbakan University, Konya, Turkey
30 Department of Medical Oncology, Gaziantep University School of Medicine, Gaziantep, Turkey
31 Department of Medical Oncology, Adıyaman Training and Research Hospital, Adıyaman, Turkey
32 Tekirdağ City Hospital, Tekirdağ, Turkey
33 Department of Medical Oncology, Pamukkale University School of Medicine, Denizli, Turkey